General FDA approves first RAS-targeted therapy for metastatic pancreatic cancerBy Healthcare Propulsion StaffAugust 27, 20260 The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic…
